More Evidence for Heart Benefits of Empagliflozin
Studies of diabetes drugs empagliflozin and dapagliflozin, both in the SGLT-2 inhibitor class, have shown they help reduce cardiovascular risk for diabetes patients. Now, researchers have found that empagliflozin is beneficial for the heart in people without diabetes as well. Read more